# Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

> **NCT00191139** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 64 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** docetaxel
- **DRUG:** cisplatin
- **DRUG:** etoposide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00191139
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2008-11
- **Final completion:** 2009-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191139, "Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00191139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*